3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Myelodysplastic Syndromes
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Myeloproliferative Disorders
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Graft vs Host Disease
3
Waldenstrom Macroglobulinemia
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Anemia, Aplastic
2
Thrombocythemia, Essential
1
Skin Neoplasms
1
Sezary Syndrome
1
Sarcoma, Myeloid
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdoid Tumor
1
Recurrence
1
Primary Myelofibrosis
1
Interventions
Cyclophosphamide
10
Magnetic Resonance Spectroscopy
8
Temozolomide
6
Biopsy
6
dinutuximab
5
X-Rays
5
Topotecan
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Irinotecan
5
Etoposide
3
Colony-Stimulating Factors
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
sargramostim
2
pembrolizumab
2
palbociclib
2
naxitamab
2
larotrectinib
2
ivosidenib
2
fludarabine phosphate
2
fludarabine
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
Lenalidomide
2
Isotretinoin
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neuroblastoma
×
Sirolimus
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled